Health TrialsbyHealthPanel

Immersive v/s Non-immersive Virtual Reality in Enhancing Upper Limb Functions Among Individuals With Subacute Stage Hemiplegia

ConditionHemiplegia and/or Hemiparesis Following Stroke
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age28-55
SponsorGulf Medical University

About this trial

The goal of this randomized controlled trial is to compare the effectiveness of immersive virtual reality combined with conventional therapy to the effectiveness of non-immersive virtual reality combined with conventional therapy in enhancing upper limb function in subacute hemiplegic stroke patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Individuals aged 28-55 years.

Diagnosed with hemiplegia due to stroke.

≤ Grade 2 on Modified Ashworth scale.

≤ Stage 2 on Brunnstrom stages of motor recovery.

Disqualifiers

Contraindications for VR therapy, such as severe motion sickness or photosensitive epilepsy, impaired spatial awareness.

Pre-existing neurological conditions such as spinal cord injury, Multiple sclerosis and so affecting upper limb function.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Oculus Quest 3

    Device

    Oculus quest 3 is a standalone virtual reality headset developed by Meta. It offers precise motion tracking and offers an innovative intervention for stroke rehabilitation, enhancing upper limb motor function throug task - specific exercises.

  • Neofect Smartboard and Tyromotion Myro

    Device

    Neofect Smart Board provides non-immersive VR rehabilitation through gamified, task specific exercises to improve upper limb mobility in an interactive way. Tyromotion Myro uses non-immersive VR therapy combining sensor-based feedback and interactive games to enhance fine motor skills.

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: Conventional Therapy + Immersive Virtual Reality TherapyExperimental treatment 1 intervention
Group B: Conventional Therapy + Non Immersive Virtual Reality TherapyExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Fugl-Meyer Assessment for upper extremity (FMA-UE)

A valid, reliable, and comprehensive measurement tool with an intra-rater reliability of ICC 0.96 and interrater reliability of ICC 0.98, used to evaluate motor impairment, balance, sensation, and joint function in the upper extremities after stroke.

Time frame
From enrollment to the end treatment at 6 weeks
2

Graded Wolf Motor function test - The WMFT

This test is designed to assess motor function, strength, and coordination in individuals with upper extremity impairments. It is a reliable measure with inter-rater reliability of 0.97 and intra-rater reliability of 0.90.

Time frame
From enrollment to the end treatment at 6 weeks

Secondary outcomes

1

Stroke Specific Quality of Life Scale (SS-QOL)

The SS-QOL scale is widely used for assessing the health-related quality of life in stroke survivors. It has a good test-retest reliability, with ICC ranging from 0.80-0.90. It is a valid and reliable tool for assessing the quality of life in stroke patients.

Time frame
From enrollment to the end treatment at 6 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Gulf Medical University

Lead sponsor

Source ClinicalTrials.gov
Apply now